Neurogene Inc. (NGNE)
NGNE Stock Price Chart
Explore Neurogene Inc. interactive price chart. Choose custom timeframes to analyze NGNE price movements and trends.
NGNE Company Profile
Discover essential business fundamentals and corporate details for Neurogene Inc. (NGNE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Mar 2014
Employees
107.00
Website
https://www.neurogene.comCEO
Rachel L. McMinn
Description
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
NGNE Financial Timeline
Browse a chronological timeline of Neurogene Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$1.40.
Earnings released on 12 May 2026
EPS came in at -$1.39 falling short of the estimated -$1.30 by -7.23%.
Earnings released on 24 Mar 2026
EPS came in at -$1.12 surpassing the estimated -$1.24 by +9.59%.
Earnings released on 13 Nov 2025
EPS came in at -$0.99 surpassing the estimated -$1.26 by +21.43%.
Earnings released on 11 Aug 2025
EPS came in at -$1.05 surpassing the estimated -$1.15 by +8.70%.
Earnings released on 9 May 2025
EPS came in at -$1.08 falling short of the estimated -$1.05 by -2.86%.
Earnings released on 24 Mar 2025
EPS came in at -$0.99 surpassing the estimated -$1.04 by +4.81%.
Earnings released on 18 Nov 2024
EPS came in at -$1.19 surpassing the estimated -$1.22 by +2.46%.
Earnings released on 9 Aug 2024
EPS came in at -$1.09 falling short of the estimated -$1.02 by -6.86%, while revenue for the quarter reached $925.00k .
Earnings released on 10 May 2024
EPS came in at -$1.00 surpassing the estimated -$1.03 by +2.91%.
Earnings released on 26 Mar 2024
EPS came in at -$1.51 falling short of the estimated -$1.17 by -29.06%.
Stock split effective on 19 Dec 2023
Shares were split 1 : 4 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$0.41 surpassing the estimated -$0.80 by +48.75%.
Stock split effective on 25 Sept 2023
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Aug 2023
EPS came in at -$0.04 surpassing the estimated -$0.15 by +73.33%.
Earnings released on 30 Mar 2023
EPS came in at -$0.26 surpassing the estimated -$4.40 by +94.18%.
Earnings released on 30 Dec 2022
EPS came in at -$0.32 surpassing the estimated -$3.80 by +91.70%.
Earnings released on 30 Sept 2022
EPS came in at -$2.36 surpassing the estimated -$6.09 by +61.16%.
Earnings released on 29 Jun 2022
EPS came in at -$0.28 surpassing the estimated -$6.00 by +95.26%.
Earnings released on 31 Mar 2022
EPS came in at -$0.28 .
Earnings released on 30 Dec 2021
EPS came in at -$0.36 surpassing the estimated -$5.96 by +94.01%.
Earnings released on 29 Sept 2021
EPS came in at -$0.28 .
NGNE Stock Performance
Access detailed NGNE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
